Zeyad Schwen, MD, highlights 5 studies in prostate cancer being presented at the 2022 American Urological Association Annual Meeting.
In this video, Zeyad Schwen, MD, discusses 5 studies in prostate cancer being presented at the 2022 American Urological Association Annual Meeting. Schwen is a urologist at the Glickman Urological & Kidney Institute, Cleveland Clinic.
The following 5 abstracts are previewed:
1. LBA01-01 (Basourakos et al): Harm-to-benefit of three decades of prostate cancer screening in Black men
2. PD03-01 (Robinsson et al): MRI as first investigation in men with elevated PSA. Population-based cohort study
3. LBA01-07 (Crawford et al): Overall safety and incidences of adverse events by time interval with darolutamide plus androgen-deprivation therapy and docetaxel in the phase 3 ARASENS trial
4. MP57-09 (Beksac et al): Comparison of Perioperative and Short-Term Functional Outcomes Between Single-Port Transvesical and Multi-Port Transperitoneal Robotic Radical Prostatectomy
5. PD17-11 (Checcucci et al): Comparison between target vs target plus standard biopsy for prostate cancer diagnosis in biopsy naive patients: a randomized controlled trial
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.